Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Equity (2016 - 2025)

Lineage Cell Therapeutics' Return on Equity history spans 15 years, with the latest figure at 1.09% for Q4 2025.

  • For Q4 2025, Return on Equity fell 83.0% year-over-year to 1.09%; the TTM value through Dec 2025 reached 1.09%, down 83.0%, while the annual FY2025 figure was 1.05%, 79.0% down from the prior year.
  • Return on Equity reached 1.09% in Q4 2025 per LCTX's latest filing, down from 0.94% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.11% in Q3 2021 to a low of 1.09% in Q4 2025.
  • Average Return on Equity over 5 years is 0.41%, with a median of 0.34% recorded in 2023.
  • Peak YoY movement for Return on Equity: surged 33bps in 2021, then tumbled -83bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.4% in 2021, then increased by 12bps to 0.35% in 2022, then grew by 5bps to 0.33% in 2023, then increased by 21bps to 0.26% in 2024, then plummeted by -316bps to 1.09% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Return on Equity are 1.09% (Q4 2025), 0.94% (Q3 2025), and 0.51% (Q2 2025).